A Randomized, Open-Label, 3-Period Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of BDP HFA Nasal Aerosol in Healthy Volunteers.

Trial Profile

A Randomized, Open-Label, 3-Period Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of BDP HFA Nasal Aerosol in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2012

At a glance

  • Drugs Beclometasone (Primary) ; Beclometasone (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 22 Feb 2012 Official title amended as reported by ClinicalTrials.gov.
    • 22 Feb 2012 Company (Teva Pharmaceutical Industries) added as trial sponsor as reported by ClinicalTrials.gov.
    • 22 Feb 2012 Additional lead trial centre, investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top